Researchers funded by NHLBI found that buprenorphine, a Schedule III drug used to treat opioid addition, could cause breathing problems in some obese patients. The discovery of the drug’s previously unknown side effect could help clinicians improve patient care. The results were published in the Online First edition of the journal Anesthesiology.
- Health Topics
- Health Education
- The Science
- Grants and Training
- News and Events
- About NHLBI